VC
HZNP

Vestor Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Vestor Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-251,889
Closed -$20.1M – 233
2022
Q2 		$20.1M Buy
251,889
+139,348
+124% +$13.2M 2.44% 11
2022
Q1 		$11.8M Buy
112,541
+74,640
+197% +$7.27M 1.18% 29
2021
Q4 		$4.08M Buy
+37,901
New +$4.13M 0.39% 62

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Vestor Capital's HZNP Position: Q3 2022 in Review

Vestor Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 251,889 shares — an estimated $20.1M sold.

Vestor Capital first reported a position in HZNP in Q4 2021 and held it in 3 quarters. The position peaked at $20.1M in Q2 2022. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • Vestor Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Vestor Capital sold 251,889 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $20.1M.
  • Vestor Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 3 quarters.
  • Vestor Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $20.1M in Q2 2022.
  • 529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Vestor Capital's 13F filing for Q3 2022, filed 14 Nov 2022.